Jazz Pharmaceuticals PLC (NAS:JAZZ)
$ 121.58 -0.01 (-0.01%) Market Cap: 7.35 Bil Enterprise Value: 10.93 Bil PE Ratio: 17.12 PB Ratio: 1.76 GF Score: 85/100

Jazz Pharmaceuticals PLC Zepzelca Update Webcast Transcript

Jun 17, 2020 / 10:15PM GMT
Release Date Price: $110.49 (-0.98%)
Katherine A. Littrell
Jazz Pharmaceuticals plc - VP of IR

Hi. This is Kathee Littrell, Head of Investor Relations at Jazz. I want to thank you all for joining us for our Zepzelca Investor Update. Before we begin the webcast, I would point out that we will be making forward-looking statements today, including statements regarding our plans and expectations for the Zepzelca commercial launch in the U.S., potential Zepzelca revenue opportunity and our other development plans and opportunities. Our forward-looking statements are subject to risks and uncertainties described in our quarterly report on Form 10-Q for the quarter ended March 31, 2020, and our other filings with the SEC, and actual results may differ materially.

We undertake no duty or obligation to update any forward-looking statements we make today. Finally, we are not confirming or updating any other guidance and actual results may differ.

I remind you that you can send in your questions. So we'd appreciate if you would send in any questions, and you can do this at any time during the presentation, and we will address your

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot